TNGX - Tango Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
TNGX price evolution
TNGX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $300.81 | $328.41 | $352.04 | $346.54 |
| Long term investments | ||||
| Property, plant & equipment | $49.02 | $50.47 | $51.61 | $53.42 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $352.42 | $381.45 | $406.22 | $402.57 |
| Current liabilities | ||||
| Accounts payable | $4.11 | $1.06 | $3.9 | $2.79 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $37.58 | $43.87 | $42.79 | $45.94 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $123.25 | $133.78 | $141.77 | $149.46 |
| Shareholders' equity | ||||
| Retained earnings | -$463.89 | -$434.72 | -$409.17 | -$371.26 |
| Other shareholder equity | $0.75 | -$0.33 | -$0.26 | $0.19 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.31 | |||
| Short term investments | ||||
| Net receivables | $2 | $2 | ||
| Inventory | ||||
| Total current assets | $346.54 | $375.27 | $492.34 | $1.5 |
| Long term investments | ||||
| Property, plant & equipment | $53.42 | $57.77 | $6.09 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $402.57 | $436.47 | $500.15 | $168.31 |
| Current liabilities | ||||
| Accounts payable | $2.79 | $4.45 | $3.23 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $45.94 | $55.55 | $40.69 | $0.11 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $149.46 | $186.99 | $155.41 | $5.95 |
| Shareholders' equity | ||||
| Retained earnings | -$371.26 | -$269.51 | -$161.34 | -$0.12 |
| Other shareholder equity | $0.19 | -$3.71 | -$0.77 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.61 | $19.88 | $6.47 | $5.43 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $44.48 | $49.43 | $48.73 | $40.44 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.05 | $0.07 | $0.04 | $0.05 |
| Interest expense | $1.81 | $2.07 | $2.2 | $2.24 |
| Net income | ||||
| Net income | -$29.17 | -$25.55 | -$37.91 | -$30.76 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.53 | $24.86 | $37.04 | |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $150.7 | $135.93 | $95.23 | $0.18 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.13 | $0.05 | $0.29 | $0.01 |
| Interest expense | $6.62 | $1.46 | $0.49 | $0.07 |
| Net income | ||||
| Net income | -$101.74 | -$108.18 | -$58.23 | -$0.12 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $34.07 | $1.5 | -$11.2 | $41.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $46.7 | $44.29 | $42.98 | $82.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$14.09 | -$15.67 | -$6.08 | $5.85 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $41.43 | $26.4 | -$183.43 | -$166.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $82.41 | $1.62 | $357.32 | $168.39 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $5.85 | -$81.06 | $114.36 | $1.31 |
News
Fundamentals
| Market cap | $805.07M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 107.41M |
| Revenue | $43.38M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$123.39M |
| Revenue Q/Q | 67.73% |
| Revenue Y/Y | 79.53% |
| P/E ratio | -6.52 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 18.56 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.15 |
|---|---|
| ROA | -32.00% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.00 |
| Quick ratio | N/A |